- Conditions
- Multiple Sclerosis
- Interventions
- Teriflunomide, Placebo (for teriflunomide)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,088 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, Placebo, MRI contrast-enhancing agents
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
- Other · Device · Dietary Supplement + 1 more
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Interventions
- Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Secondary-progressive Multiple Sclerosis
- Interventions
- Mayzent, Ocrevus
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
- Conditions
- Multiple Sclerosis
- Interventions
- ELND002, Placebo
- Drug
- Lead sponsor
- Elan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 17
- States / cities
- Berkeley, California • Fresno, California • Newport Beach, California + 14 more
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
- Interventions
- Caprylic Triglyceride, Placebo
- Dietary Supplement
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- Interventions
- Foralumab TZLS-401 50 µg
- Drug
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 25 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Alpha Lipoic Acid
- Drug
- Lead sponsor
- Rebecca Spain
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis), MS, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Sclerosis, Relapsing-remitting, Multiple Sclerosis, Secondary Progressive
- Interventions
- Not listed
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Interventions
- Tovaxin Autologous T Cell Vaccine
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • Houston, Texas
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 889 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- [C11]PK-1195 PET scan
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Progressive Multiple Sclerosis, Hemiparesis
- Interventions
- Gaming CI Therapy
- Behavioral
- Lead sponsor
- University of Massachusetts, Lowell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Interventions
- estriol, Placebo, Norethindrone, Progestin Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, standard of care
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more